XRTX
vs
S&P 500
XRTX
S&P 500
Over the past 12 months, XRTX has underperformed S&P 500, delivering a return of -46% compared to the S&P 500's +15% growth.
Stocks Performance
XRTX vs S&P 500
Performance Gap
XRTX vs S&P 500
Performance By Year
XRTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
XORTX Therapeutics Inc
Glance View
XORTX Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-09-30. The firm is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) due to coronavirus infection. Its lead product candidates are XRx-008, XRx-101 and XRx-225. XRx-008 is a late clinical stage program focused on demonstrating the potential of its therapy for ADPKD. XRx-101 is a program to treat acute kidney injury associated with Coronavirus/ COVID-19 infection, AKI and associated health consequences. XRx-225 is a program for the treatment of T2DN. The company is also working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
